Novo Nordisk (NYSE: NVO) remains the dominant force in the rapidly expanding metabolic health market, continuing to experience unprecedented demand for its semaglutide products. Recent…
February 12, 2026
June 18, 2024
The GLP-1 Gold Rush Continues
A 2024 report from GlobalData has revealed that in spite of approaching headwinds in the obesity market, glucagon-like peptide-1 (GLP-1) receptor agonists will continue to…